Nippon India Taiwan Equity Fund- Direct Plan- Growth Option vs HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan
A side-by-side comparison of returns, cost, size and risk. These funds sit in DIFFERENT categories, so their returns are not directly comparable — they are exposed to different assets and risks.
NAV as of 17 Nov 2026. Returns over 1 year are annualised. Past performance does not indicate future returns, and this comparison is not a recommendation.
| Metric | Nippon India Taiwan Equity Fund | HDFC Pharma and Healthcare Fund |
|---|---|---|
| Category | Thematic Fund | Sectoral/ Thematic |
| Fund house | Nippon India Mutual Fund | HDFC Mutual Fund |
| NAV | ₹24.9992 | ₹23.411 |
| 1Y return | +93.62% | +15.90% |
| 3Y return | +57.04% | +27.97% |
| 5Y return | — | — |
| AUM | ₹1,147 Cr | ₹3,501 Cr |
| Expense ratio | 1.07% | 1.05% |
| Risk | Very High | Very High |
Highlighting marks the higher return or lower cost on rows where both funds have data. It is arithmetic, not advice — a cheaper or higher-returning fund is not automatically the better choice for you.